Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.

Trial Profile

Interferon (IFN) induction followed by PEG-interferon combined with ribavirin and amantadine for treatment of naive chronic hepatitis C patients with genotype 1 or 4.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Nov 2017

At a glance

  • Drugs Amantadine; Interferon; Peginterferon; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms VKF3
  • Most Recent Events

    • 28 Aug 2010 Status changed from completed to active, no longer recruiting as reported by Netherlands Trial Register.
    • 28 Aug 2009 Additional trial identifier NTR560 identified as reported by ISRCTN: Current Controlled Trials.
    • 18 Aug 2009 Status changed from not stated to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top